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Abstract
Background: HIV-associated general immune activation is a strong predictor for HIV disease progression,
suggesting that chronic immune activation may drive HIV pathogenesis. Consequently, immunomodulating agents
may decelerate HIV disease progression.
Methods: In an observational study, we determined immune activation in HIV patients receiving low-dose (5 mg/
day) prednisolone with or without highly-active antiretroviral therapy (HAART) compared to patients without
prednisolone treatment. Lymphocyte activation was determined by flow cytometry detecting expression of CD38
on CD8(+) T cells. The monocyte activation markers sCD14 and LPS binding protein (LBP) as well as inflammation
markers soluble urokinase plasminogen activated receptor (suPAR) and sCD40L were determined from plasma by
ELISA.
Results: CD38-expression on CD8+ T lymphocytes was significantly lower in prednisolone-treated patients
compared to untreated patients (median 55.40% [percentile range 48.76-67.70] versus 73.34% [65.21-78.92], p =
0.0011, Mann-Whitney test). Similarly, we detected lower levels of sCD14 (3.6 μg/ml [2.78-5.12] vs. 6.11 μg/ml [4.58-
7.70]; p = 0.0048), LBP (2.18 ng/ml [1.59-2.87] vs. 3.45 ng/ml [1.84-5.03]; p = 0.0386), suPAR antigen (2.17 μg/ml
[1.65-2.81] vs. 2.56 μg/ml [2.24-4.26]; p = 0.0351) and a trend towards lower levels of sCD40L (2.70 pg/ml [1.90-4.00]
vs. 3.60 pg/ml [2.95-5.30]; p = 0.0782). Viral load in both groups was similar (0.8 × 105 ng/ml [0.2-42.4 × 105] vs. 1.1
× 105 [0.5-12.2 × 105]; p = 0.3806). No effects attributable to prednisolone were observed when patients receiving
HAART in combination with prednisolone were compared to patients who received HAART alone.
Conclusions: Patients treated with low-dose prednisolone display significantly lower general immune activation
than untreated patients. Further longitudinal studies are required to assess whether treatment with low-dose
prednisolone translates into differences in HIV disease progression.
Background
Progressive depletion of helper T cells is a hallmark of
untreated HIV infection. There is accumulating evidence
that chronic immune activation may be a fundamental
driving force of this T cell loss. HIV infection triggers a
general activation of the immune system that persists
for years, which may eventually result in exhaustion of
the regenerative capacities of the immune system,
causing immunodeficiency and AIDS [1-3]. The trigger
for this chronic stimulation is probably multifactorial,
including a direct stimulation of HIV-specific cells by
the ongoing replication of HIV [4]. Furthermore, ele-
vated levels of plasma lipopolysaccharide (LPS) and bac-
terial DNA in chronic HIV patients suggest that
microbial translocation from the damaged gut contri-
butes to this hyperactivation by triggering an innate
immune response to Gram-negative bacteria [5,6]. Dur-
ing this process, the two host factors LPS binding pro-
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direct it to the Toll-like receptor (TLR)-4 molecule
expressed on macrophages [7,8].
The pivotal role of chronic immune activation in HIV
pathogenesis is underlined by the fact that immune activa-
tion parameters such as expression of CD38 or HLA-DR
on CD8+ T are good predictors of subsequent T cell loss
and correlate much better with HIV disease progression
than plasma viral load or chemokine coreceptor usage [2].
In a similar way, plasma levels of soluble sCD14, LBP and
soluble urokinase plasminogen activator receptor (suPAR)
correlate with HIV disease progression [2,9,10]. The trans-
membrane glycoprotein CD40L (CD154), a member of the
tumor necrosis factor family, is primarily expressed on
activated CD4+ T cells, but also detected on many other
cell populations including a small proportion of CD8+
cells [11]. The soluble form (sCD40L) still binds to the
receptor and delivers biological signals in a cytokine-like
manner [12]. Increased sCD40L levels were detected in
the serum of HIV-infected patients [13].
Chronic immune activation as a consequence of
immunodeficiency virus infection is restricted to man
and Asian monkeys, who both develop AIDS following
untreated HIV/SIV infection. In contrast, African mon-
keys which do not exhibit chronic immune activation
following SIV infection do not progress to AIDS and
remain healthy, despite high viral load [6,14,15].
Treatment with antiretroviral therapy does not only sup-
press virus replication but also substantially reduces HIV-
associated general immune activation [16-21]. Compared
to uninfected controls, HAART-treated patients however
still exhibit slightly elevated immune activation that is
being considered a risk factor for ongoing disease progres-
sion (albeit at much slower pace than in untreated
patients) [22-27]. Despite the dramatic success of antire-
troviral therapy on reduction of mortality in HIV infection,
HIV-infected patients treated with HAART still have a life
expectancy below the average of the uninfected population
[28]. Immune-based therapies that aim to further reduce
immune activation under HAART may therefore further
close this gap. In resource-limited areas with later onset of
HAART compared to more industrialized countries, cheap
and robust immunomodulating regimens preceding anti-
retroviral therapy may be another option to reduce world-
wide HIV mortality until HAART becomes universally
available.
In this study we investigated general immune activa-
tion in HIV patients who received low-dose (5 mg/day)
prednisolone in combination with or without HAART
compared to untreated patients.
Methods
Subjects
The patients analyzed in this study received HIV-treat-
ment according to the treatment recommendations of
the “Deutsche AIDS Gesellschaft” (DAIG). In addition
to antiretroviral medication, some of our patients also
received low-dose (5 mg/day) prednisolone as part of
their individual treatment plan. Among the 101 HIV
patients included into our study, 27 received low-dose
(5 mg/day) prednisolone, 31 received low-dose predni-
solone in combination with HAART, 30 received
HAART alone and 13 received neither HAART nor
prednisolone.
Prednisolone medication
We (A. Ulmer) have previously reported that HIV
patients who do not yet meet the eligibility criteria for
antiretroviral therapy seem to profit from treatment
with low-dose (5 mg per day) prednisolone by a stabili-
zation of helper T cell counts compared to patients that
remained therapy-naive [29,30]. Due to these encoura-
ging observations, patients at the site of A. Ulmer are
being offered low-dose prednisolone (prior or accompa-
nying to HAART) and patients decide individually of
whether or not to receive prednisolone. We therefore
supervise a population of patients that can be categor-
ized into four subgroups: untreated-patients, predniso-
lone-treated patients, and at later stages of the infection
HAART-treated patients who receive or do not receive
prednisolone. All patients investigated in this study
derive from the same study center (A. Ulmer), which
was the only participating site that could enroll predni-
solone-treated patients. To compare immune activation
in patients with therapeutic (HAART) and immunologic
control of virus replication, we included 3 additional
treatment-naïve patients (elite controllers who suppress
virus replication beyond the detection limit of 50
copies/ml) from another site (H. Klinker).
Study design
In an observational study we compared immune activa-
tion parameters in 5 different subject groups: (1) HIV-1-
infected subjects who receive neither HAART nor pre-
dnisolone and with detectable viral load, referred to as
“untreated"; (2) HIV-1 infected subjects treated with 5
mg/day prednisolone, referred to as “Prednisolone"; (3)
HIV-1 infected subjects treated with antiretroviral ther-
apy, referred to as “HAART"; (4) HIV-infected subjects
treated with antiretroviral therapy in combination with
5 mg/day prednisolone, referred to as “HAART+Predni-
solone"; (5) HIV-1 infected subjects as described for (1)
but with undetectable viral load referred to as “elite con-
trollers”. Patients have been asked to participate in the
study during their routine visits at the site. Patients will-
ing to participate in the study signed an informed con-
sent. No additional selection criteria other than
willingness to participate were applied for inclusion into
the study.
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The study was approved by the ethical committees of
the Landesärztekammer Baden-Württemberg, the Bayer-
ische Landesärztekammer, and the University of
Würzburg.
Isolation of plasma
7.5 ml of whole blood were collected from each patient
with a vacutainer supplemented with EDTA (BD Bios-
ciences) for flow cytometric analysis of PBMC. EDTA
plasma was used for sCD40L-ELISA. Additional 8 ml of
blood were collected for plasma preparation from
heparin-blood. Heparin-plasma was used for sCD14-
and LBP-ELISAs.
Flow cytometry
Fresh EDTA-blood was used within 8 h after collection.
Erythrocytes were lysed using a lysis solution (BD Bios-
ciences) and PBMC were stained in triplicates with anti-
bodies directed at CD3 (labeled with FITC) and CD8+
(labeled with PerCP) and counterstained with anti-
CD38-PE (all antibodies from were purchased from BD
Biosciences, Heidelberg, Germany) according to the
“lysis no wash” protocol (BD Biosciences). Cells were
analyzed by flow cytometry using a FACS-Calibur flow
cytometer (Becton Dickinson). Markers were set accord-
ing to cells stained with fluorochrome-conjugated iso-
type control antibodies (all from BD Biosciences).
Lymphocytes were identified by gating in a dot plot of
forward and sideward scatter (FSC/SSC). For analysis of
T cell activation, cells were stained with anti-CD3
(PerCP)/CD8(FITC)/CD38(PE)-antibodies. CD3+/CD8+
cells within the FSC/SSC lymphocyte gate were scored
as CD8+ T-lymphocytes. CD3+/CD8- cells within the
FSC/SSC lymphocyte gate were scored as CD4-positive
T cells. CD38 expression was determined in CD3+/CD8
+ lymphocytes (CD8 T lymphocytes) and CD3+/CD8-
lymphocytes (scored as CD4+ T lymphocytes). CD38+
lymphocytes were scored as activated cells. For analysis
of naïve T cells, cells were stained with anti-CD3
(PerCP)/CD4(APC)/CD45RA(FITC)/CD62L(PE)-antibo-
dies. CD3+/CD4+ cells within the FSC/SSC lymphocyte
gate were scored as CD4+ T-lymphocytes. CD3+/CD4-
cells within the FSC/SSC lymphocyte gate were scored
as CD8-positive T cells. CD45RA/CD62L-expression
was determined in CD3+/CD4+ lymphocytes (CD4 T
lymphocytes) and CD3+/CD4- lymphocytes (scored as
CD8+ T cells). CD45RA/CD62L-positive lymphocytes
were scored as naïve cells.
Viral load and CD4 counts
CD4 counts and viral load were determined from
EDTA-blood by a commercial virusdiagnostic laboratory
during routine medical care (CD4: Prof. Enders, Stutt-
gart, viral load: Dr. Jaegel-Guedes/Jäger, München).
sCD14, LBP, suPAR and sCD40L
ELISAs to detect plasma levels of sCD14 (Diaclone),
LBP (Hycult Biotech), suPAR (ViroGates) and sCD40L
(Bender MedSystems) were performed according to the
manufacturer’s instructions. For the latter, 100 μl of
EDTA plasma samples were analyzed that had been
thawed once.
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism software (version 4.0c for Macintosh). About half
of the data showed a non-Gaussian distribution (accord-
ing to D’Agostino-Pearson test) so that medians and
interquartile range (expressed as 25%-75% percentile)
were chosen to describe the results. Differences between
untreated and Prednisolone-treated or HAART-treated
and HAART + Prednisolone-treated groups were ana-
lyzed by Mann-Whitney U-test and p < 0.05 was
regarded as statistically significant. Correlations were
performed using linear regression.
Results
Patient population
In this observational study we analyzed general immune
activation parameters in patients with HIV infection
receiving individual therapy regimes. Patients who were
willing to participate in the study gave written informed
consent and donated a single blood sample. We divided
the patients into five different groups, including a)
untreated patients (n = 10), b) patients being treated
with low-dose prednisolone (n = 27), c) with HAART (n
= 30), d) HAART plus prednisolone (N = 31) or e)
treatment-naïve patients with undetectable viral load
(Table 1). At the time of blood sampling, the 27 patients
in the prednisolone group received prednisolone medi-
cation for a median duration of 2.3 years (Table 1).
Although the exact time of infection for each patient is
unknown, the date of the first HIV diagnosis indicates
that patients in the prednisolone and HAART groups
are probably much longer infected with HIV (median of
9 years in both HAART groups and median of 5 years
in the prednisolone-only group) than patients in the no-
treatment group (median of 2 years) (Table 1).
Values represent medians [interquartile range as 25%-
75% percentile]. *) As the number of elite controllers in
this study is only 3, all three single values are depicted
instead of the median. Cutoff for viral load (VL) for all
patients is 40 copies/ml plasma, except for the three
patients (elite controllers) derived from H. Klinker with
a detection limit of 50 copies/ml. Values in double
brackets [[x]] represent VL of individual HAART-treated
patients with detectable VL. **) For 7 patients treated
with HAART+prednisolone the exact time of predniso-
lone treatment was unknown but their medical records
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documented treatment for more than 5 years. For the
calculation of the median, the time of treatment for
these patients was set to 5 years
Viral load
Patients in the no-treatment and prednisolone-treatment
groups presented with comparable amounts of viral load
(medians 1.1 × 105 and 0.8 × 105, respectively) (Table
1). Most of the patients who received HAART (both in
combination with or absence of prednisolone) had unde-
tectable viral load (below 40-50 copies/ml).
CD38-expression on T cells
T cell activation was studied by flow cytometric analysis
of whole blood stained with anti-CD3/CD8/CD38. CD3-
positive/CD8-negative cells were scored as CD4-positive
T lymphocytes. Patients in the prednisolone group
exhibited statistically significant lower activation of CD8
+ T cells than patients in the untreated group patients
(median 55.40% [percentile range 48.76-67.70] versus
73.34% [65.21-78.92], p = 0.0011). (Figure 1A). The low-
est activation rates were measured in HAART and
HAART+prednisolone-treated patients (median 22.07%
[15.49-38.27] versus 28.85% [20.69-36.87]) and predniso-
lone comedication had no detectable effect on CD8-acti-
vation in HAART-treated patients (p = 0.2515). CD38-
expression on CD8 T cells in patients receiving HAART
was similar to CD38 expression in “elite controllers” but
due to the very limited number of patients in this group
(n = 3) we will not go into further details.
Prednisolone medication had apparently no effect on
CD38 expression in CD8-negative T cells, independent
of whether patients received prednisolone in the absence
or presence of HAART (Figure 1B)
sCD14 and LBP
In order to determine the effects of low-dose predniso-
lone on monocyte activation associated with the LPS-
response, we analyzed levels of soluble CD14 (sCD14)
and LPS-binding protein (LBP). We found significantly
lower concentrations of plasma sCD14 in patients trea-
ted with prednisolone alone compared to untreated
patients (3.6 μg/ml [2.78-5.12] vs. 6.11 μg/ml [4.58-
7.70]; p = 0.0048) (Figure 2A). No effects attributable to
prednisolone could be observed in HAART-treated
patients. Similar to what we found for sCD14 levels,
patients in the prednisolone-only group showed signifi-
cantly lower LBP-levels compared to untreated
patie2Ants (2.18 ng/ml [1.59-2.87] vs. 3.45 ng/ml [1.84-
5.03]; p = 0.0386) (Figure 2B), and again no additional
effects related to prednisolone were observed in
HAART-treated patients.
suPAR and sCD40L
Comparing patients treated with prednisolone alone and
untreated patients, significantly lower concentrations of
plasma suPAR levels were detected in prednisolone-trea-
ted patients (2.17 μg/ml [1.65-2.81] vs. 2.56 μg/ml [2.24-
4.26]; p = 0.0351) as well as a strong trend towards
lower levels of sCD40L (2.70 pg/ml [1.90-4.00] vs. 3.60
pg/ml [2.95-5.30]; p = 0.0782) (Figure 3B). In the pre-
sence of HAART, no effects attributable to prednisolone
could be observed for the two markers (Figure 3A, B).
CD4 T cell counts, CD4/CD8 ratio and naïve cells
As depicted in Figure 4A, patients treated with predni-
solone-only presented with CD4+ T cell counts compar-
able to untreated patients (550 cells/μl [460-700] vs. 520
cells/μl [350-670]; p = 0.7067). Patients treated with
HAART or HAART/prednisolone exhibited a trend
towards lower CD4 T cell counts compared to therapy
naïve and prednisolone-treated patients. The CD4/CD8
ratio in prednisolone-only-treated patients was signifi-
cantly decreased compared to treatment-naïve patients
(ratio 0.46 [0.38-0.72] vs. ratio 0.755 [0.55-0.97]), and
comparable to HAART and HAART/prednisolone-trea-
ted patients (Figure 4B). As the CD4+ T cell counts in
prednisolone-treated and naive patients are similar
Table 1 Patient characteristics
Treatment group Untreated (n =
10)
Prednisolone (n
= 27)
HAART Prednisolone/HAART no treatment, elite
controllers
number of patients 10 27 30 31 3
age in years 39 [28.0-50.5] 38 [32.0-47.0] 47 [42.5-61.0] 48 [40.0-58.0] 28, 43, 56*
sex m/f 9 m/1 f 22 m/5 f 24 m/6 f 23 m/8 f 2 m/1 f
time since first HIV
diagnosis in years
2 [1.0-4.0] 5 [3.0-13.0] 9 [4.5-16.0] 9 [3.0-14.0] 3, 15, 21*
prednisolone treatment
in years
n.a. 2.3 [1.2-3.5] n.a. 5 [2.0-5.7]** n.a.
viral load (RNA copies/ml
plasma)
1.1 × 105 [0.5-
12.2 × 105]
0.8 × 105 [0.2-
42.4 × 105]
27 undetectable, others
[[46;66;191]]
25 undetectable, others: [[41; 46;
63; 74; 131; 1085]]
undetectable
CD4+ counts (cells/μl) 520 [350-670] 550 [460-700] 465[320-655] 390[280-600] 284, 554, 892*
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Figure 1 Prednisolone medication in untreated HIV infection is associated with lower CD8+ T cell activation. Whole blood from donors
of different treatment groups was stained with fluorescent dye-coupled anti-CD3, anti-CD8 and anti-CD38 antibodies. Cells were analyzed by
flow cytometry after erythrocyte lysis. Lymphocytes were gated in a FSC/SSC scatter. CD3+/CD8+ cells from the lymphocyte gate were scored as
CD8+ T cells, CD3+/CD8- cells were scored as CD4+ T cells. Horizontal bars represents medians. Statistical analysis was performed using a Mann-
Whitney U test. A: Percentage of CD8+ T cells expressing CD38. B: Percentage of CD4+ T cells expressing CD38
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Figure 2 Prednisolone medication in untreated HIV infection is associated with lower monocyte activation. sCD14 and LBP
concentrations were determined by ELISA from plasma from donors of different treatment groups. Horizontal bars represents medians. Statistical
analysis was performed using a Mann-Whitney U test. A: Plasma concentrations of sCD14. B: Plasma concentrations of LBP.
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Figure 3 Prednisolone medication in untreated HIV infection is associated with lower inflammation. Concentrations of suPAR and
sCD40L were determined by ELISA from plasma from donors of different treatment groups. Horizontal bars represents medians. Statistical
analysis was performed using a Mann-Whitney test U-test. A: suPAR. B: sCD40L.
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(Figure 4 A), the decrease of the observed CD4/CD8
ratio in prednisolone-treated patients reflects a relative
increase of the CD8+ T cell population. This increase
could be a direct consequence of the observed reduced
immune activation of this population (Figure 1A), which
may translate into reduced turnover rates.
In patients treated with HAART, prednisolone-medi-
cation was associated with a significantly higher percen-
tage of memory (CD62L+/CD45RA+) CD8+ T cells
(23.8% [12.6 - 39.1] vs. 15.8% [9.84-22.25]; p = 0.0372)
(Figure 4C) and memory CD4+ T cells (25.4% [18.3 -
44.6] vs. 18.8% [10.9-30.85]; p = 0.0268) (Figure 4D). No
Figure 4 The influence of prednisolone on CD4 counts, CD4/CD8 ratio and naïve T cells. CD4 counts and CD4/CD8 ratio were determined
from blood samples by routine diagnostic. Whole blood from donors of different treatment groups was stained with fluorescent dye-coupled
anti-CD3, anti-CD4, anti-CD62L and anti-CD45RA antibodies. Cells were analyzed by flow cytometry after erythrocyte lysis. Lymphocytes were
gated in a FSC/SSC scatter. CD3+/CD4+/CD62L+/CD45RA cells from the lymphocyte gate were scored as naïve CD4+ T cells, CD3+/CD4-/CD62L
+/CD45RA cells were scored as naïve CD8+ T cells. Horizontal bars represent medians. Statistical analysis was performed using a Mann-Whitney
test. A: absolute CD4+ T cell counts. B: CD4/CD8 T cell ratio. C: percentage of naïve CD8+ T lymphocytes. D: percentage of naïve CD4+ T
lymphocytes.
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effects attributable to prednisolone on the frequency of
naive T cells were detected between untreated and pre-
dnisolone-only-treated patients.
Discussion
In this study we investigated factors of general immune
activation associated with HIV disease progression, and
we found significantly lower values in patients receiving
prednisolone compared to untreated patients, suggesting
that prednisolone may have beneficial effects on immu-
nological correlates of HIV disease progression in other-
wise untreated patients. In patients treated with
HAART, no additional beneficial effects attributable to
prednisolone could be observed. The immune-modulat-
ing activity of prednisolone in otherwise untreated
patients described in this manuscript is in line with pre-
vious observations, reported by Andrieu et al., who
observed in an uncontrolled, open-label study an
increase in CD4+ T cell counts following administration
of 0.3-0.5 mg/kg prednisolone over a period of 12
months [31]. Prednisolone treatment (with a concentra-
tion about 4-8 times higher than in our study) was
accompanied by a reduction of immune activation.
Patients were encouraged to continue 0.3 mg/kg predni-
solone as follow up-medication as long as their CD4+ T
cell levels remained above baseline levels. Follow-up
prednisolone treatment postponed CD4+ T cell decrease
(relative to baseline levels) by two years [32]. A few
patients experienced relatively mild prednisolone-asso-
ciated side effects such as face swelling, an increase in
body weight and elevated blood pressure.
In another, randomized, placebo-controlled trial, pre-
dnisolone was given for 8 weeks with a decreasing dose
from 50 mg to 15 mg per day; the main outcome was
survival [33]. Elliot and colleagues observed only a trend
towards better survival in prednisolone-treated patients
compared to HIV controls (21 versus 25 deaths per 100
person years; difference statistically not significant) but a
statistically significant increase in the incidence of
Kaposi sarcoma (4.2 versus 0 cases per 100 person
years). The study population was not being stratified for
HHV-8 seropositivity, the causative factor of Kaposi sar-
coma, and HHV-8 infection status was not being ana-
lyzed. (In another short-term randomized, placebo-
controlled trial studying the effects of prednisolone on
effusive tuberculous pericaditis in HIV-infected indivi-
duals, with a similar dosage and time scale [60 mg start-
ing dose, tapered with 10 mg per week until completion
at the sixths week], three cases of Kaposi sarcoma were
observed among the 58 study participants and all of
them received placebo [34].) The main difference in the
treatment regime towards other studies, including ours,
is the relative short duration of prednisolone treatment
of only 8 weeks, which may hamper the observation of a
therapeutic benefit with the primary endpoint of
survival.
Two other randomized, placebo-controlled trials
investigated the effects of prednisolone on HIV-infection
in the presence of HAART. In a study with a dose of 0.5
mg per kg body weight per day given for 8 weeks, a
decrease in CD8+/CD38+ cells was reported with no
changes in viral load and CD4+ cell counts [35]. In par-
tial contrast to this, a fixed daily dose of 40 mg predni-
solone was given for 8 weeks in another trial, resulting
in an increase of CD4+ counts compared to baseline
values of 40%, but no changes in HLADR/CD38-positive
CD8 cells and naive T cells (CD45RA+/CD62L+) were
reported [36].
We have previously analyzed the CD4+ cell counts of
some of our patients in a longitudinal observational
study and found that long-term treatment with low-dose
prednisolone is safe and - similar to what has been
found by Andrieu et al. [31] - associated with a post-
ponement of CD4+ T cell loss by about 2 years relative
to baseline values [29,30]. Our present study may offer a
mechanistic explanation for the T cell preserving activity
of low-dose prednisolone, i.e. by reducing general
immune activation. Unfortunately, the previously
described CD4+ T cell preserving activity of predniso-
lone cannot be directly addressed in this study (although
a trend towards higher counts in prednisolone-treated
patients was visible), as this would require a longitudinal
analysis and probably also a more homogenous patient
sample with respect to time to infection and therapy
initiation.
The strong association between general immune acti-
vation and HIV disease progression is also seen in stu-
dies investigating the effects of HAART on immune
activation. Similar to what we found in our study,
HAART does not only suppress virus replication but
also reduces immune activation [18-20]. In some
patients - the so-called virological nonresponders -
HAART fails to suppress virus replication but effectively
restores immune activation and CD4 T cell counts [37].
On the other hand, immunological nonresponders, who
do not regenerate helper T cell counts despite HAART-
mediated suppression of virus replication, show
enhanced immune activation [38]. Massanella et al.
reported in a cross sectional study that patients with
limited CD4 T-cell repopulation under HAART exhib-
ited high T-cell activation rates (CD38+, HLA-DR+),
suggesting that immunomodulating strategies should be
envisaged to treat discordant patients [39].
General immune activation not only correlates with
progression of immunodeficiency, but also with neurolo-
gical complications of HIV infection. HIV patients with
cognitive impairment or brain atrophy exhibit more ele-
vated sCD14 levels than neurologically asymptomatic
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HIV-positive controls [40]. This link between monocyte
activation and the neurological complications of HIV
infection fits well into the overall picture in which
microglia activation has been identified as a correlate
with immunodeficiency virus-mediated neuropathy
[41,42].
Due to the non-prospective and non-randomized
design of our study, our findings should be interpreted
with caution, as potential yet undiscovered confounding
mechanisms may have biased the result. Moreover, the
low sample size of our study is relatively low and differ-
ences in individual viral loads (although not statistically
significant between untreated and prednisolone-treated
patients) are possible limitations. As we found signifi-
cantly lower immune activation in patients treated with
prednisolone compared to untreated patients, the critical
reader might object that this difference might have been
caused by an unintended enrichment of natural slow-
progressors in the group of prednisolone-treated
patients over time, who would lower the average
immune activation in this group due to intrinsically
lower immune activation in these patients. (The argu-
ment in this case would be that patients who progressed
under prednisolone sooner or later would have left this
group to become treated with HAART. Hence, over
time, patients with an intrinsic slower disease progres-
sion would have become enriched in this group. At a
closer look, this mechanism would, however, also apply
for patients in the untreated group - compared to which
prednisolone-treated patients exhibited significantly
lower activation.) We therefore checked whether there
is any correlation in prednisolone-treated patients
between immune activation (CD8/CD38, sCD14, LBP,
suPAR) and the duration of prednisolone medication or
the (known) time of infection and found no correlation
whatsoever for any of the markers (P values of correla-
tions ranged between 0.2748 and 0.9399, data not
shown). These findings suggest that a prednisolone-
independent enrichment over time of slow-progressing
patients in this group has not taken place, otherwise
one should have expected to observe lower levels of
immune activation in patients with longer treatment
times.
As for the absence of detectable effects of predniso-
lone in HAART-treated patients in almost all analyzed
parameters in this study, this may well be attributed to
the heterogeneity of the patients (differences in CD4
counts, time to infection), differences in the composition
of individual antiretroviral regimens that may have dif-
ferent effects on immune activation or to the low dose
of prednisolone used. Further studies specifically addres-
sing the effects of prednisolone in the presence of
HAART looking at more homogenous patient groups
are therefore needed. Studying the effects of immune
modulators in the presence of HAART (in contrast to
immune modulators preceding HAART) is of particular
interest, since there is residual immune activation in
HAART-treated patients associated with accelerated dis-
ease progression [25].
In countries with lesser access to (and therefore later
onset of) HAART, prednisolone medication preceding
antiretroviral treatment might be considered as a sup-
plement regimen in HIV therapy, provided that predni-
solone-mediated immune modulation is safe and
translates into a clinical benefit for the patients. In
order to address this question, we are currently per-
forming a randomized, double-blinded, placebo-con-
trolled clinical trial to assess the effects of low-dose
prednisolone on immune activation and HIV disease
progression in otherwise treatment-naïve patients,
recruiting 326 patients in Tanzania (trial name: “Pro-
Cort1"; registry: http://ClinicalTrials.gov; registration
number: NCT01299948). Recruitment is now completed
and first results will be available soon.
Conclusions
General immune activation is considered to be a key
factor for HIV disease progression and the results of our
study indicate that treatment with low-dose predniso-
lone may reduce this activation. Further studies are
required to analyze whether attenuation of immune acti-
vation achieved by immunomodulatory substances
translates into clinical benefit for the patients.
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